Tian Gao

Tian Gao

Auto-generated profile, based on publicly available information

Tian Gao

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Bone and Soft Tissue Tumor, Peking University Cancer Hospital and Institute, Beijing, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
ZTZhichao Tan
Zhichao Tan
YWYan Wu
Yan Wu
ZFZhengfu Fan
Zhengfu Fan
TGTian Gao
Tian Gao
WGWei Guo
Wei Guo
JLJiayong Liu
Jiayong Liu
Purpose: Alveolar soft part sarcoma (ASPS) is an ultrarare soft-tissue sarcoma with a high rate of metastasis and no established treatment. This study aimed to explore the efficacy and safety of anlotinib (a tyrosine kinase inhibitor) and TQB2450 (a PD-L1 inhibitor) in patients with ASPS. Patients and Methods: This single-arm, phase II study evaluated the efficacy of TQB2450, an anti–PD-L1 agent, combined with anlotinib, a tyrosine kinase inhibitor, in adults with advanced ASPS. TQB2450 was given intravenously (1,200 mg) on day 1, and anlotinib (12 mg/day) was taken orally from day 1 to 14 every 3 weeks. The primary endpoint was overall response rate, with secondary endpoints including duration of response, progression-free survival, and overall survival. Lymphocyte infiltration and tertiary lymphoid structure (TLS) were also analyzed as potential prognostic biomarkers. Results: The study enrolled 29 patients, of whom 28 were evaluable (one withdrew because of acute pancreatitis). An objective response was achieved in 82.1% of patients, including 4 complete and 19 partial responses. The median time to response was 2.8 months, and the duration of response was not reached, with an estimated median progression-free survival of 35.2 months. Grade 3 to 4 treatment-related adverse events occurred in 44.8% of patients, with no study-related deaths. Responders had a higher proportion of TLS area, TLS density, and CD20-positive immune cells. Conclusions: The combination of anlotinib and TQB2450 is effective and tolerable in patients with ASPS. TLS may serve as a prognostic biomarker, meriting further investigation.

13 August 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
ZTZhichao Tan
Zhichao Tan
JRJiayin Ruan
Jiayin Ruan
YWYan Wu
Yan Wu
ZFZhengfu Fan
Zhengfu Fan
CBChujie Bai
Chujie Bai
JLJiayong Liu
Jiayong Liu
Purpose: Alveolar soft part sarcoma (ASPS) is an ultrarare soft tissue sarcoma. Current standard therapy with PD-1/PD-L1 inhibitors achieves limited response rates (<40%). Lymphocyte-activation gene 3 (LAG-3) is coexpressed with PD-1 on exhausted T cells, and dual blockade has shown synergy in some solid tumors but remains unexplored in sarcoma. This trial evaluated the efficacy of IBI110 (anti–LAG-3) plus sintilimab (anti–PD-1) in advanced ASPS. Patients and Methods: This open-label, phase II study enrolled 28 patients from July 2022 to September 2023 (median follow-up, 33.6 months). Both drugs were given intravenously at 200 mg every 3 weeks. The primary endpoint was overall response rate (ORR) by RECIST v1.1. Results: Among 28 patients, 8 (28.6%) were resistant to prior immune checkpoint inhibitors (ICI), and 20 (71.4%) were ICI-naïve. The overall ORR was 51.8% (14/27 evaluable), including 4 complete responses and 10 partial responses. During a median follow-up of 33.6 months, the median progression-free survival (PFS) and overall survival (OS) were not reached in the whole population. In ICI-naïve patients, the ORR was 60%, with median PFS/OS not reached. In ICI-resistant patients, the ORR was 25%, with median PFS of 14.9 months and median OS of 25.4 months. The median time to response was 3.3 months; the median duration of response (DoR) was not reached. Grade 3 to 4 treatment-related adverse events occurred in nine patients (32.1%), with no treatment-related deaths. Exploratory analysis showed that responders had significantly higher baseline LAG-3+ cell density in tumor specimens. Conclusions: Dual LAG-3/PD-1 blockade demonstrated promising and durable antitumor activity with manageable safety in both ICI-naïve and ICI-resistant advanced ASPS, warranting further investigation.